Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy by Hatswell, AJ et al.
Target journal: Pharmacoeconomics 
Article type: Original article or systematic review 
Title: Economic evaluations of pharmaceuticals without randondomised controlled trials: a 
systematic review and taxonomy  
 
Anthony J Hatswell MSc1, 2, Nick Freemantle PhD3, Gianluca Baio PhD1 
1 Department of Statistical Science, University College London, Gower Street, WC1E 6BT 
2 BresMed, 84 Queen Street, Sheffield, S1 2DW 
3 Department of Primary Care and Population Health, University College London, Gower 
Street, WC1E 6BT 
 
Key words: historical control; non-randomised; single group study, health technology appraisal, cost-
effectiveness 
  
Abstract (247 / 250) 
Background 
Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised 
controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised 
comparator group (either active or placebo).  
Objective 
To identify and develop a taxonomic account of economic modelling approaches for pharmaceuticals 
licensed without randomised control trial data. 
Methods 
We searched PubMed, the websites of UK health technology assessment (HTA) bodies and the ISPOR 
Scientific Presentations Database for assessments of the 74 indications granted a marketing 
authorisation by the FDA or EMA from Jan-1999 to May-2014 without RCT data. The outcome of 
interest was the approach to modelling efficacy data. 
Results 
Fifty-one unique models were identified based on 29 peer-reviewed articles, 30 health technology 
appraisals (HTAs), and 15 ISPOR abstracts concerning 30 indications (44 indications had not been 
modelled). Also notable was the low rate of submission to HTA agencies (28/98).The majority of 
models (43/51) were based on ‘historical controls’ – comparisons to previous meta-analysis or 
pooling of trials (5), individual trials (19), registries/case series (14), or expert opinion (7). Other 
approaches used the patient as their own control, performed threshold analysis, assumed time on 
treatment was added to overall survival, or performed cost-minimization. 
Conclusions 
There is considerable variation in the quality and approach of models constructed for drugs granted 
a marketing authorisation without a RCT. The most common approach is of a naïve comparisons to 
historical data (using other trials / registry data as a control group), with considerable scope for bias. 
  
Key points for decision makers 
 When pharmaceuticals are licensed without comparative data, economic models are 
generally constructed using a historical control 
 Even within evaluations using the same method, the quality and appropriateness of an 
approach varies 
 The appropriateness of historical comparison for modelling using uncontrolled study data 
requires further methodological evaluation 
  
Article: Word count: 2261 
1. Introduction 
Treatments are usually granted a marketing authorisation on the basis of randomised controlled 
trials, conducted against either a placebo or an active control[1]. This provides a good basis for 
regulators to make decisions regarding the efficacy of interventions compared to the current 
standard of care [2]. This evidence may then be used to estimate the difference between the new 
treatment and the standard of care. Indirect treatment comparisons using a common comparator 
sometimes enable the comparison of the efficacy of treatments in different studies[3,4]. 
Less commonly, treatments can be granted a marketing authorisation without a study containing a 
control arm. In a few cases it may be ‘obvious’  that the treatment is efficacious, for example if all 
patients died before an intervention was available, but all live afterwards[5], or patients achieve a 
marked improvement in an objective measure, for example blood count[2]. Whilst these treatments 
may receive a license for their use, estimates of their comparative efficacy compared to the 
currently used treatment are still needed to inform decisions on reimbursement in many healthcare 
systems. This may be to show the clinical improvement for patients, or alternatively for cost-
effectiveness analysis, used in many countries for resource allocation decisions[3].  
Where cost-effectiveness analysis is used as a criterion in healthcare systems, treatments are 
required to generate more health (usually defined in terms of quality adjusted life years) than the 
treatments that would be displaced (represented by a ‘shadow budget’), i.e. that the money spent 
on the new intervention would not be better spent elsewhere. How such estimates should be 
constructed without controlled trials is however unclear – whilst there exists extensive guidance on 
constructing economic models based on RCT results, there is no guidance on the most appropriate 
method of modelling uncontrolled study data from health technology agencies or professional 
bodies (Table 1). 
The objective of this study was therefore to identify models constructed for treatments granted 
marketing authorisation without controlled clinical trial evidence, and the approach taken to 
estimating relative efficacy between the treatment(s). Of relevance to the study were both 
published economic models and health technology appraisals. 
 
2. Methods 
Hatswell et al. [6] identified 74 indications granted a marketing authorisation by either the FDA or 
the EMA from 1999 to May 2014, on the basis of uncontrolled clinical trial results. We conducted a 
systematic review for economic evaluations published for each of the treatments listed using 
PubMed (search terms given in Figure 1). Searches were also conducted for health technology 
appraisals conducted by the National Institute for Health and Care Excellence (NICE), the Scottish 
Medicines Consortium (SMC), and All Wales Medicines Strategy Group (AWMSG), as well as the grey 
literature of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
Scientific Presentations Database. 
After identification, results (papers, health technology appraisal submissions and scientific 
presentations) were filtered for models constructed in the relevant indications with uncontrolled 
study data (some treatments had multiple indications, which was what the publication investigated, 
or subsequently had RCTs conducted). Results were then de-duplicated based on the model 
descriptions and study authors, to account for the same model being used for different purposes (for 
example a model used in a NICE submission, then published with Spanish costs, all whilst using the 
same approach to modelling efficacy). Where it was not clear whether a model was reported on 
multiple occasions, or was a similar approach, this was discussed by the reviewers and a decision 
reached by consensus. 
Following identification of the economic models, the approaches used to estimate efficacy against 
the relevant comparator were categorised for each model. If a model included multiple approaches 
to modelling efficacy data, these were classed as separate approaches. The resulting models were 
then placed in to a taxonomic framework and analysed for commonality in approach. 
 
3. Results 
Figure 2 shows the PRISMA diagram for economic evaluations retrieved through PubMed [7]. The 
initial 74 searches yielded 1202 hits, which were reduced to 56 full articles after abstract and title 
review. Twenty nine papers were included in the final analysis. The main reasons for exclusion on full 
paper review were models being based on RCT data (n=9), considering a different indication 
(including a different stage of the same disease, n=7) and papers that did not contain an economic 
model (e.g. burden of illness studies, n=6).  
In addition to published papers searches of health technology body websites led to 19 NICE 
appraisals being identified (9 included), 52 SMC appraisals identified (16 included), and 27 AWMSG 
appraisals identified (5 included). Overall there was a notable level of non-submission to HTA 
agencies, in particular to the SMC (13/52 non-submissions) and AWMSG (13/27 non-submissions). 
Appraisals also often occurred after RCT based results had become available (NICE 8/19, SMC 9/52, 
AWMSG 3/27) leading to exclusion from this study. Full results of the review are shown in Table 1.  
Searching the ISPOR Scientific Presentations Database led to 1780 abstract hits, with 43 records 
selected for further review and 29 full records included. The most common reason for exclusion was 
insufficient information reported regarding the model or approach used (n=14). 
In total, 74 relevant documents were identified (including publications, health technology appraisals 
and scientific presentations), which described 91 distinct modelling approaches. After consolidation 
of approaches reported multiple times (for example one model being used for NICE and SMC 
submissions, presented at ISPOR and then published in an indexed journal), 51 unique approaches 
were identified. Of these 51 models, the overwhelming majority (n=43, 84%) were based on 
historical controls. Other approaches identified included using patients as their own control either 
through statistical analysis or comparisons with baseline values (n=3, 6%), cost minimisation 
analyses (n=3, 6%), threshold analyses (n=1, 2%), or assuming in oncology that time in progression 
free survival was added to overall survival, with treatments then given in sequence (termed the 
‘cumulative method’; n=1, 2%) (Figure 3). 
All the 43 historical controls identified compared the results of the uncontrolled study of the new 
treatment to a separate set of data. In 17 cases (40%) the new treatment was compared to one arm 
from another clinical study and in 5 cases (12%) pooled or meta-analysed data from a series of 
studies. A further 14 models (33%) used comparisons to registry or case series data, with 7 models 
(16%) comparing the results of the uncontrolled study to expert opinion. Trial and registry data 
appeared to be used interchangeably in evaluations, with only seven studies (16%) attempting to 
account for differences in patient characteristics or patient selection. 
 
4. Discussion 
The results of this review show that 51 unique models have been published for 30 different 
indications granted a marketing authorisation without a comparative trial. Consequently of the 74 
indications approved without a comparative trial, [6] 44 indications have therefore not been 
modelled and estimates of cost-effectiveness are available. It is not known what the rate of 
economic evaluation of new indications is, although we suspect it will be higher than the 40% rate 
seen in this study. 
The use of historical control was by far the most common approach (43/51), which was most 
frequently taken from another trial or trials (22 of the 43). However, even within this method there 
was substantial variation – some studies compared the results of uncontrolled trials to results taken 
from multiple trials (for example Dinnes et al. who pooled the results of 8 other clinical trials to 
compare against), whereas the majority of models compared against single arms from other studies.  
The assumption inherent in naïve comparisons to historical controls (first proposed by Pocock[8]) is 
that patients are similar, or “exchangeable”, between studies. If this is not the case, and patient 
systematically differ, then this procedure will introduce bias in the results. Several approaches to 
matching patients and baseline characteristics between studies are available in the literature, 
including methods based on propensity scores,[9] and match adjusted indirect comparisons [10]. 
Despite the availability of these approaches, only 2 models attempted to control for any differences 
between trials, with one notable outlier being the work by Annemans et al. [11], who constructed a 
historical control by reviewing patient records at the centres that participated in the clinical trial, in 
the time period before the clinical trial was open for enrolment [11]. 
The lack of adjustment of outcomes to reflect potentially more favourable patient cohorts may 
represent a substantial bias in the literature in favour of the new treatments. A study by Sacks, 
Chalmers & Smith of 50 RCTs and 56 historically controlled trials of the same interventions, the 
randomised control arm performed better than the historical control arm. In the studies cited 
therefore 79% of historically controlled trials stated the intervention was effective, compared to only 
20% of RCTs[12]. Diehl & Perry investigated the same question looking at overall survival or relapse 
free survival in oncology, finding 43 examples in the literature of well-matched historical cohorts and 
RCT control groups. However when comparing the outcomes of the two groups, 18 of the 43 studies 
had a greater than 10% difference in effect size between the control groups – the randomised group 
performing better on 17/18 occasions [13]. This latter finding is particularly concerning given 32 of 
the 43 historically controlled models were in oncology, though other examples historical controls 
have proved a poor match for RCT control arms that would be expected to have shown similar 
results. [14–16] 
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Outside of historical controls, cost minimisation (though frowned upon in the literature[17]) was 
used in 3 models – whilst it may appear superficially attractive to assume treatments have equal 
efficacy to similar ones, it is unlikely that they exhibit exactly the same efficacy, with zero 
uncertainty. A further 3 models compared patient outcomes on treatment to a patient’s baseline 
result. This is also a potentially biased approach, due to issues such as regression to the mean[18]. 
One additional approach, comparing all patients to non-responders, allows the estimation of an 
effect size; however it will be overly favourable towards the intervention, as non-responders will 
include an inherently sicker population [19]. The final approach noted was that of Tappenden et al., 
who pragmatically performed threshold analysis of the relative risk needed for the drug to be 
considered cost-effective. Although this does not necessarily give an estimate of effect size, it allows 
a decision maker to make a more informed decision after reviewing the clinical evidence[20], as such 
we would recommend the use of similar threshold analyses where appropriate. 
That there is a number of differing approaches to modelling, with a lack of standard approach to 
handling issues such as patient selection, is likely a reflection of the relative rarity of evaluations with 
this type of data (we identified only 51 models, compared to the vast literature of health economic 
evalatons published[21]). Despite the lack of standard approaches and guidelines however, some 
studies appear to be well conducted, with attempts to select an approach based on reasonable 
assumptions, and control for any patient selection (for example Woods et al.[22]).  
 
5. Conclusion 
The majority of treatments granted a marketing authorisation without controlled study results have 
not been subject to economic evaluation in a published form, with also a high level of non-
submission to UK health technology agencies for such products. The evaluations that have been 
performed were generally based on naïve comparisons to historical controls from individual arms of 
clinical trials, or registry/case series data. 
Further research and guidance is required on the appropriateness of historical controls in economic 
evaluation, and on the most relevant methods to use when modelling uncontrolled data with the 
aim of estimating comparative effectiveness. Ultimately formal guidance and standardisation may 
reduce the level of bias in economic evaluations, and lead to an improvement in the average quality 
of published models. Standardisation would also provide a basis for comparison between studies, 
such that interventions can be more readily compared with other approaches to evaluation, where 
methods are comparable [23]. 
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Tables & Figures 
Table 1: Tabulated PRISMA diagram of the number and source of economic evaluations identified 
as being based on uncontrolled clinical study data 
  NICE SMC AWMSG ISPOR PubMed Totals 
Number of hits 19 52 27 1793 1235 3182 
Non-submissions 2 13 13 - - 28 
For review 17 39 14 43 56 142 
Excluded 8 23 9 28 27 95 
Different indication 0 0 1 2 7 11 
Different drug or intervention 0 0 0 4 3 7 
Clinical paper or commentary 0 0 0 1 1 2 
Not an economic model 0 5 0 2 6 13 
Model based on RCT data 8 9 3 5 9 33 
Insufficient information 0 9 5 14 1 29 
Included 9 16 5 15 29 74 
 
Table 2: Economic models identified as having been based on uncontrolled clinical study data 
Drug Disease area Approach taken 
Historical 
control? 
Source of 
historical 
data 
Data 
adjusted? 
Year Reference 
Anagrelide Essential thrombocytopenia Decision tree comparing outcomes with treatment to patient 
baseline 
No - - 1999 [24] 
Anagrelide Essential thrombocytopenia Markov model using other expert opinion on the efficacy of 
treatments 
Yes Expert 
opinion 
- 2002 [25] 
Anagrelide Essential thrombocytopenia Markov model using historical control data from a trial for 
the main comparator and no treatment 
Yes Trial - 2005 [26] 
Argatroban Heparin-induced 
thrombocytopenia 
Trial data used for the drug, with historical data from the 
same hospitals involved in the trial used for the comparator 
Yes Case series - 2006 [27] 
Argatroban Heparin-induced 
thrombocytopenia 
Trial data used for the drug, with case series data used for 
the control 
Yes Case series - 2007 [28] 
Argatroban Heparin-induced 
thrombocytopenia 
Decision tree model using historical control data from 
hospitals for both treatment and control 
Yes Case series - 2012 [29,30] 
Argatroban Heparin-induced 
thrombocytopenia 
Decision tree model using an assumption of equal efficacy 
(cost minimisation) 
-  - 2013 [31] 
Busulfan Haematopoietic progenitor cell 
transplantation 
Decision tree model using unadjusted trial results to 
compare the treatment and comparator 
Yes Trial - 2012 [32] 
Temozolomide Anaplastic astrocytoma Compares trial results to a meta-analysis of trials of the 
comparator treatment 
Yes Meta-
analysis 
- 2000 [33] 
Temporfin Head and neck cancer Trial results for the treatment compared naively to the 
control arm of a clinical trial for another treatment 
Yes Trial - 2004, 
2005 
[34,35] 
Gemtuzumab 
Ozogamicin 
Acute myeloid leukaemia Trial data for the drug compared with hospital data for the 
comparator. The group were matched for demographics 
Yes Case series Yes 2002 [36] 
Alemtuzumab Chronic lymphocytic leukaemia Assumption made of identical efficacy between products, 
with naïve comparison of trials used as sensitivity analysis 
- - - 2007 [37] 
Imatinib Mesylate Chronic myeloid leukaemia Single arm study used for treatment results, which are 
compared (unadjusted) to the results of the comparator 
taken from an RCT 
Yes Trial - 2002-
2004 
[38–40] 
Imatinib Mesylate Chronic myeloid leukaemia Single arm study used for treatment results, which are 
compared to expert opinion for the comparator 
Yes Expert 
opinion 
- 2002- 
2003 
[38,40,41] 
Imatinib Mesylate Gastrointestinal stromal 
tumours 
Exponential curve fitted to the trial data for imatinib, naively 
compared to a historical control from a trial 
Yes Trial - 2003 - 
2007 
[42–44] 
Imatinib Mesylate Gastrointestinal stromal 
tumours 
Trial data for imatinib compared to a case series for the 
comparator 
Yes Case series - 2003 [45] 
Cetuximab Colorectal cancer Trial data used for cetuximab, with the comparator 
effectiveness estimated by reducing the survival based on 
results from another trial 
- - Yes 2007 [46,47] 
Cetuximab Colorectal cancer Trial data used for cetuximab, using a naïve comparison to 
results from another trial which included the comparator 
Yes Trial - 2007 [20,48] 
Cetuximab Colorectal cancer Trial data used for cetuximab, with threshold analysis 
performed how ineffective the comparator would need to 
make cetuximab cost-effective 
- - - 2007 [20,48] 
Cetuximab Colorectal cancer Trial data used for cetuximab, with case series data taken 
from the same hospitals used as the control arm 
Yes Case series - 2007 [11] 
Trabectedin Soft tissue sarcoma Uncontrolled trial data compared naively to pooled data 
from two trials for the comparator (ifosfamide) 
Yes Pooled trial 
data 
- 2008- 
2011 
[49–52] 
Trabectedin Soft tissue sarcoma Uncontrolled trial data for trabectedin compared with 
pooled data from four trials for the comparator, with 
adjustments made to account for differences in baseline 
characteristics 
Yes Pooled trial 
data 
Yes 2009-
2013 
[53–57] 
Trabectedin Soft tissue sarcoma Progression free survival taken from studies of the 
comparators then compared naively. All patients then 
assumed to have equal post progression survival 
Yes Pooled trial 
data 
- 2014 [58,59] 
Cladribine Hairy cell leukaemia Naïve historical control of results pooled trial data clinical 
trials. Results from the studies were adjusted for patient 
disease status, but not demographic characteristics 
Yes Pooled trial 
data 
Yes 2007 [60] 
Gefitinib Non-small cell lung cancer Naïve comparison of gefitinib uncontrolled clinical study to 
the best supportive care arm from a RCT in the same disease 
area 
Yes Trial - 2004 [61] 
Clofarabine Acute lymphoblastic leukaemia Compared outcomes from the drug to results from a registry 
matched to patient characteristics 
Yes Registry Yes 2006, 
2007 
[62,63] 
Nelarabine T-cell acute lymphoblastic 
leukaemia / lymphoma 
Trial data for Nelarabine compared to historical trial data for 
the comparator 
Yes Trial - 2008, 
2009 
[64,65] 
Betaine Anhydrous Homocystinuria Decision tree comparing results of an uncontrolled study to 
results seen in a registry 
Yes Registry - 2010 [66] 
Alglucosidase Alfa Pompe disease Uncontrolled data compared to matched registry data Yes Registry Yes 2007, 
2012 
[67,68] 
Alglucosidase Alfa Pompe disease Trial data compared naively to registry data from the disease 
area 
Yes Registry - 2014 [69] 
Sunitinib Malate Renal cell carcinoma Uncontrolled trial data compared to a published case series 
and a Medicare case series 
Yes Case series - 2007, 
2009 
[70–73] 
Sunitinib Malate Renal cell carcinoma Expert opinion used to estimate the benefit of sunitinib Yes Expert 
opinion 
- 2007 [74] 
Sunitinib Malate Renal cell carcinoma Trial data for sunitinib compared to a Finnish case series Yes Case series - 2007, 
2008 
[75,76] 
Dasatinib Chronic myeloid leukaemia Uncontrolled study data for dasatinib compared to trial data 
for the comparator 
Yes Trial - 2007, 
2009 
[77–79] 
Dasatinib Chronic myeloid leukaemia Uncontrolled study data for dasatinib compared to trial data 
for the comparator 
Yes Trial - 2007, 
2009 
[77–80] 
Dasatinib Philadelphia chromosome-
positive acute lymphoblastic 
leukaemia 
Historical control for the comparator compared to trial data 
for dasatinib 
Yes Trial - 2007 [80] 
Bortezomib Mantle cell lymphoma Trial data compared to historical control taken from a 
Canadian cancer registry 
Yes Registry - 2009 [81] 
Nilotinib 
Hydrochloride 
Monohydrate 
Chronic myeloid leukaemia Results from clinical trials for each of the comparators used 
in the model without adjustment 
Yes Trial - 2008, 
2009 
[78,82] 
Nilotinib 
Hydrochloride 
Monohydrate 
Chronic myeloid leukaemia Uncontrolled study results for each of the comparators Yes Trial - 2011 [83] 
Nilotinib 
Hydrochloride 
Monohydrate 
Chronic myeloid leukaemia Response rates taken from clinical studies for each of the 
comparators, then used to predict survival based on this 
surrogate outcome 
Yes Trial - 2009 [84] 
Tocofersolan Vitamin E deficiency due to 
cholestasis 
Trial results for the treatment, with expert opinion used for 
the comparator 
Yes Expert 
opinion 
- 2012 [85] 
Ofatumumab Chronic lymphocytic leukaemia Non-responders assumed to represent the outcome for 
untreated patients 
- - - 2010- 
2013 
[19,86–
89] 
Carglumic acid Chronic hyperammonemia Comparator data taken from an Italian hospital Yes Case series - 2013 [90] 
Asparaginase Erwinia 
Chrysanthemi 
Acute lymphoblastic leukaemia Assumption made of equal efficacy for all treatments (cost-
minimisation) 
- - - 1995 [91] 
Brentuximab Vedotin Hodgkin's lymphoma Trial data used for the drug, with a systematic review 
conducted for comparator data, which was then adjusted for 
differences in patient characteristics between trials 
Yes Trial Yes 2012 [22] 
Defibrotide Veno-occlusive disease Trial data used for defibrotide, with then selected patients 
from a case series used for comparator data 
Yes Historical 
control 
Yes 2014 [92] 
Bosutinib Chronic myeloid leukaemia Surrogate outcome of response rate taken from each 
comparator and used to estimate outcomes 
Yes Trial - 2013 [93–95] 
Bosutinib Chronic myeloid leukaemia Time on treatment for each drug assumed to be additive to 
estimate overall survival 
- - - 2013 [93,96] 
Bosutinib Chronic myeloid leukaemia Trial data for the drug compared to expert opinion of 
survival for untreated patients 
Yes Expert 
opinion 
- 2013 [95] 
Bosutinib Chronic myeloid leukaemia Trial data for the drug compared to expert opinion of 
survival for untreated patients 
Yes Expert 
opinion 
- 2013 [95] 
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Figure 2: PRISMA diagram of economic evaluations retrieved from PubMed 
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Figure 3: Taxonomy of economic modelling approaches used for estimating incremental benefit 
from uncontrolled clinical studies 
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